甾醇调节元件结合蛋白
脂肪生成
脂肪肝
内分泌学
内科学
酒精性脂肪肝
酒精性肝病
肝X受体
转录因子
生物
化学
脂质代谢
胆固醇
医学
核受体
生物化学
甾醇
基因
肝硬化
疾病
作者
Don-Kyu Kim,Yong-Hoon Kim,Jae-Ho Lee,Yoon Seok Jung,Jina Kim,R Feng,Tae Il Jeon,Inkyu Lee,Suengmok Cho,Seung Soon Im,Steven Dooley,Timothy F. Osborne,Chul-Ho Lee,Hueng Sik Choi
标识
DOI:10.1016/j.bbalip.2019.158521
摘要
Although SREBP-1c regulates key enzymes required for hepatic de novo lipogenesis, the mechanisms underlying transcriptional regulation of SREBP-1c in pathogenesis of alcoholic fatty liver is still incompletely understood. In this study, we investigated the role of ERRγ in alcohol-mediated hepatic lipogenesis and examined the possibility to ameliorate alcoholic fatty liver through its inverse agonist. Hepatic ERRγ and SREBP-1c expression was increased by alcohol-mediated activation of CB1 receptor signaling. Deletion and mutation analyses of the Srebp-1c gene promoter showed that ERRγ directly regulates Srebp-1c gene transcription via binding to an ERR-response element. Overexpression of ERRγ significantly induced SREBP-1c expression and fat accumulation in liver of mice, which were blocked in Srebp-1c-knockout hepatocytes. Conversely, liver-specific ablation of ERRγ gene expression attenuated alcohol-mediated induction of SREBP-1c expression. Finally, an ERRγ inverse agonist, GSK5182, significantly ameliorates fatty liver disease in chronically alcohol-fed mice through inhibition of SREBP-1c-mediated fat accumulation. ERRγ mediates alcohol-induced hepatic lipogenesis by upregulating SREBP-1c expression, which can be blunted by the inverse agonist for ERRγ, which may be an attractive therapeutic strategy for the treatment of alcoholic fatty liver disease in human.
科研通智能强力驱动
Strongly Powered by AbleSci AI